Luye Pharma Group (HK:2186) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Luye Pharma Group has announced the inclusion of several innovative drugs, including Ruoxinlin and Baituowei, in China’s 2024 National Reimbursement Drug List. This development is expected to enhance patient access and accelerate commercialization, potentially boosting financial returns for the company. The inclusion marks a significant milestone for Luye’s proprietary antidepressant, Ruoxinlin, as a breakthrough ‘Made-in-China’ drug.
For further insights into HK:2186 stock, check out TipRanks’ Stock Analysis page.
